In Brief: Sequus
Executive Summary
Sequus: Licenses Sheffield Medical Technologies' liposome-CD4 technology as a potential HIV/AIDS therapeutic, companies announce July 22. Terms of the licensing agreement include a signing fee, payable to Sheffield in Sequus common stock, milestone payments and royalties. Menlo Park, Calif.-based Sequus also will continue funding of some CD4-related laboratory work...